Factors influencing hematopoietic recovery after autologous blood stem cell transplantation in patients with acute myeloblastic leukemia and with non-myeloid malignancies
- 1 May 2002
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 29 (10), 825-832
- https://doi.org/10.1038/sj.bmt.1703566
Abstract
Factors influencing hematopoietic recovery (HR) after autologous blood stem cell transplantation (ABSCT) were analyzed in 73 patients with various non-myeloid malignancies (NMM), and in 58 patients with acute myeloblastic leukemia (AML). Peripheral blood stem cells were collected following mobilization with chemotherapy, granulocyte colony-stimulating factor (G-CSF), or chemotherapy plus G-CSF. The conditioning regimen used consisted of either chemotherapy alone (112 cases) or chemotherapy plus total body irradiation (19 cases). The median number of colony-forming units granulocyte–macrophage (CFU-GM) was similar in both groups of patients, with the median number of CD34+ cells infused being higher in the AML group (5.4 vs 4 × 106/kg; P = 0.03). Median time neutrophils >0.5 × 109/l was 13 days in both groups, and median time to a platelet count >20 × 109/l was longer in AML patients (14 vs 12 days; P = 0.01). In multivariate analysis, the only factors affecting neutrophil recovery in the NMM group were the CD34+ cell number (continuous model) and the CFU-GM dose (categorized model) infused, whereas for platelet recovery, previous chemotherapy also remained significant. In the AML group, the only factors significantly affecting the speed of neutrophil recovery were dose of CD34+ cells administered and the patient's age. As for platelet recovery, only the progenitor dose administered remained significant. In the NMM group, the most discriminating cut-off values for a rapid neutrophil and platelet recovery were 1.5 × 106 and 2.5 × 106 CD34+ cells/kg, respectively, and for AML patients these figures were 1.5 × 106 and 4 × 106 CD34+ cells/kg, respectively. Our results confirm the slower HR after ABSCT in AML, and highlight the importance of progenitor cell dose in accelerating HR after ABSCT.Keywords
This publication has 16 references indexed in Scilit:
- Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?Bone Marrow Transplantation, 1999
- Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: a retrospective analysis of a 10-year single institution experienceBone Marrow Transplantation, 1998
- Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcomeBone Marrow Transplantation, 1998
- Autologous peripheral blood stem cell transplantation for acute myelogenous leukemiaBone Marrow Transplantation, 1997
- Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitorsBone Marrow Transplantation, 1997
- Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantationBone Marrow Transplantation, 1997
- Multivariate analyses of prognostic factors associated with hematopoietic recovery in autograft patients with different sources of progenitor cellsAnnals of Oncology, 1996
- The ISHAGE Guidelines for CD34+ Cell Determination by Flow CytometryJournal of Hematotherapy, 1996
- Autografting with blood progenitor cells: predictive value of preapheresis blood cell counts on progenitor cell harvest and correlation of the reinfused cell dose with hematopoietic reconstitutionAnnals of Hematology, 1995
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958